Tag: Imugene
Imugene: Progresses VAXINIA trial in December quarter
Imugene Progresses VAXINIA trial in December quarterImugene (IMU) has taken another step forward in its efforts to treat and eradicate tumours in cancer...
Imugene: Receives VAXINIA ethics approval in Australia
Imugene Receives VAXINIA ethics approval in AustraliaImugene (IMU) receives Human Research Ethics Committee (HREC) approval to commence a phase one clinical trial of...
Imugene: Presents fresh onCARlytics data at SITC annual meeting
Imugene Presents fresh onCARlytics data at SITC annual meetingImugene (IMU) presents new data for its onCARlytics oncolytic virus at the Annual Meeting of...
Imugene: Generates income of $5.34m in H1 FY22
Imugene Generates income of $5.34m in H1 FY22Imugene (IMU) records an income of more than $5.34 million for the half-year ending December 31,...
Imugene: Receives $4.8M tax rebate on cancer research
Clinical-stage immuno-oncology company Imugene (IMU) has received a hefty tax rebate for its research and development (R&D) spending
The company has banked a...
Imugene: Receives FDA approval for PD1-Vaxx trial
Imugene (IMU) has received approval from the U.S. Food and Drug Administration (FDA) to begin a clinical trial for its PD1-Vaxx drug
Then...